Heron Therapeutics, Inc. (NASDAQ:HRTX) shares advanced 2.12% in last trading session and ended the day at $18.33. HRTX has a return on assets of -73.40%. Heron Therapeutics, Inc. (NASDAQ:HRTX) quarterly performance is -33.37%.
Heron Therapeutics, Inc. (NASDAQ:HRTX) announced that the U.S. Food and Drug Administration (FDA) has informed the Company that it anticipates concluding its review of the New Drug Application (NDA) of SUSTOL®(granisetron) Injection, extended release, by early April 2016. The Company is working closely with the FDA to facilitate the completion of its review.
Orient Paper, Inc. (NYSEMKT:ONP) ended the last trading day at $1.31. Company weekly volatility is calculated as 5.68% and price to cash ratio as 6.05. Orient Paper, Inc. (NYSEMKT:ONP) showed a weekly performance of 0.77%.
Orient Paper, Inc. (NYSEMKT:ONP) announced its unaudited preliminary results for the fourth quarter and the fiscal year ended December 31, 2015. The Company anticipates filing its 2015 annual report on Form 10-K with the Securities and Exchange Commission and releasing its earnings after the market closes on Wednesday, March 23, 2016. The Company will host a conference call to discuss its fourth quarter and fiscal year 2015 financial results at 8:00 am Eastern Time (5:00 am Pacific Time/ 8:00 pm Beijing Time) on Thursday, March 24, 2016.
On 10 March, Freeport-McMoRan Inc. (NYSE:FCX) shares advanced 4.92% and was closed at $9.60. FCX EPS growth in last 5 year was -34.90%. Freeport-McMoRan Inc. (NYSE:FCX) year to date (YTD) performance is 41.80%.
Freeport-McMoRan Inc (NYSE:FCX)‘s stock had its “sell” rating reissued by analysts at Citigroup Inc. in a research note issued on Tuesday, MarketBeat reports.
Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) shares fell -7.01% in last trading session and ended the day at $5.44. DRNA has a return on assets of -56.50%. Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) quarterly performance is -58.97%.
Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) announced financial and operational results for the quarter and full year ended December 31, 2015. During the fourth quarter of 2015, Dicerna established safety for DCR-MYC at the 1.0 mg/kg level. This dose level corresponds to drug exposure levels that show efficacy in mouse tumor models.
U.S. Auto Parts Network, Inc. (NASDAQ:PRTS) caters to the Services space. It has a net profit margin of -1.20% and weekly performance is 3.02%. On the last day of trading company shares ended up at $3.07. U.S. Auto Parts Network, Inc. (NASDAQ:PRTS) distance from 50-day simple moving average (SMA50) is 5.62%.
U.S. Auto Parts Network, Inc. (NASDAQ:PRTS) has been invited to present at the 28th Annual ROTH Capital Partners Conference being held March 13-16, 2016 at the Ritz Carlton in Dana Point, California.
Leave a Reply